Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26652153 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL13222901 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL12253802 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL10001262 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL14622977 | 0.87 | — | — | |
| SCHEMBL14624334 | 0.85 | — | — | |
| SCHEMBL18098021 | 0.85 | — | — | |
| SCHEMBL21123603 | 0.85 | — | — | |
| SCHEMBL22317546 | 0.85 | — | — | |
| SCHEMBL14537126 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-9566293-B2 | Oral delivery of therapeutically effective LNA oligonucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20160340382-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-11-24 | — | — | US | disclosed |
| US-9364495-B2 | Oral delivery of therapeutically effective LNA oligonucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2016-06-14 | — | — | US | disclosed |
| US-20160032289-A1 | Oral Delivery of Therapeutically Effective LNA Oligonucleotides | SANTARIS PHARMA A/S (DK) | 2016-02-04 | — | — | US | disclosed |
| US-9249175-B2 | RNA monomers containing O-acetal levulinyl ester groups and their use in RNA microarrays | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-02-02 | — | — | US | disclosed |
| US-20120322851-A1 | ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| US-20120178638-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322851-A1 | ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES | SLC10A1, SLC2A8, SLC2A4 | FGF1 1103/4885 |
| US-20160340382-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | EFTUD2, RNMT, RNGTT | FGF1 4331/4885 |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | DNAJC13, DNAJC5, DNAJC7 | FGF1 4811/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | FGF1 4492/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | FGF1 3381/4885 |
| US-20160032289-A1 | Oral Delivery of Therapeutically Effective LNA Oligonucleotides | SLC10A1, SLC2A8, SLC2A4 | FGF1 1103/4885 |
| US-20120178638-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | EFTUD2, RNMT, RNGTT | FGF1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.